Osteoarthritis treatment with Hyalgan - an HTA

Maschoreck T
Record ID 32002000822
Authors' objectives:

This report aims to assess whether Hyalgan is an adequate treatment offer for patients with osteoarthritis.

Authors' recomendations: If the treatment is introduced it should be applied for patients who have been slightly or moderately affected, while more serious cases should be offered alloplastics. Introduction of the treatment in hospitals would imply - besides an investment of 900,000 DKK for drug expenses - half a permanent post for a nurse and half a permanent post for a junior doctor, corresponding to a total expense of around 1,200,000 DKK. The consequences of introducing the treatment in private practices should be the subject of a thorough political discussion and further clarification before this solution is chosen. It should be considered whether it is appropriate to wait for the results from the Glostrup study before it is finally decided if Hyalgan should be offered to patients with Osteoarthritis.
Authors' methods: Overview
Project Status: Completed
URL for project: http://www.sst.dk/
Year Published: 2000
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Denmark
MeSH Terms
  • Costs and Cost Analysis
  • Osteoarthritis
Organisation Name: Danish Centre for Evaluation and Health Technology Assessment
Contact Address: National Board of Health, PO Box 1881, Islands Brygge 67, DK-2300 Copenhagen S, Denmark. Tel: 45 72 22 74 48; Fax: 45 72 22 74 07/67
Contact Name: dacehta@sst.dk
Contact Email: dacehta@sst.dk
Copyright: Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) (formerly DIHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.